![]() Tato From Data to Understanding through Systems Biology Thomas Hagan and Bali Pulendran Systems Biology Views of Vaccine Innate and Adaptive Immunity Rino Rappuoli, Emilio Siena, and Oretta Finco What Really Constitutes the Study of “Systems Biology” and How Might Such an Approach Facilitate Vaccine Design Ronald N. Shlomchik WILL SYSTEMS BIOLOGY DELIVER ITS PROMISE AND CONTRIBUTE TO THE DEVELOPMENT OF NEW OR IMPROVED VACCINES? Seeing the Forest Rather than a Few Trees Mark M. McHeyzer-Williams, Chad Dufaud, and Michael G. ![]() Macpherson DO MEMORY B CELLS FORM SECONDARY GERMINAL CENTERS? Impact of Antibody Class and Quality of Memory T-Cell Help at Recall Louise J. Littman Issues of Sovereignty, Federalism, and Points-Testing in the Prokaryotic and Eukaryotic Spaces of the Host-Microbial Superorganism Andrew J. DO THE MICROBIOTA INFLUENCE VACCINES AND PROTECTIVE IMMUNITY TO PATHOGENS? Engaging Our Endogenous Adjuvants Nicholas Collins and Yasmine Belkaid If So, Is There Potential for Efficacious Microbiota-Based Vaccines? Dan R. McDermott Potential for a Universal Influenza Vaccine James E. Yewdell Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Kissick IS IT POSSIBLE TO DEVELOP A “UNIVERSAL” INFLUENZA VIRUS VACCINE? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine Florian Krammer, Adolfo García-Sastre, and Peter Palese Outflanking Antibody Immunodominance on the Road to Universal Influenza Vaccination Davide Angeletti and Jonathan W. Schoenberger Neoantigens as Vaccine Targets for Cancer Haydn T. Finn and Hans-Georg Rammensee Targeting the Right Antigens in the Right Patients Stephen P. Halstead The Challenges of a Dengue Vaccine Gavin Screaton and Juthathip Mongkolsapaya IS IT POSSIBLE TO DEVELOP CANCER VACCINES TO NEOANTIGENS, WHAT ARE THE MAJOR CHALLENGES, AND HOW CAN THESE BE OVERCOME? Neoantigens: Nothing New in Spite of the Name Olivera J. Vaccine Bruno Guy There Is Only One True Winner Scott B. de Silva and Eva Harris Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Whitehead and Kanta Subbarao The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials Aravinda M. Haynes WHICH DENGUE VACCINE APPROACH IS THE MOST PROMISING, AND SHOULD WE BE CONCERNED ABOUT ENHANCED DISEASE AFTER VACCINATION? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination Stephen S. ![]() Victora and Hugo Mouquet Breaking through Immunity's Glass Ceiling Garnett Kelsoe and Barton F. Wilson Lessons from the Antibody Response to HIV-1 Gabriel D. Sze, and Yang Zhang Is Affinity Maturation a Self-Defeating Process for Eliciting Broad Protection? Christopher T. Johnson and Golnaz Vahedi T-Cell Heterogeneity Plasticity and Selection in Humans Federica Sallusto, Antonino Cassotta, Daniel Hoces, Mathilde Foglierini, and Antonio Lanzavecchia Complexities of Interpretation due to the Heterogeneity of Memory CD4 T Cells, Including T Follicular Helper Cells Shane Crotty WHAT ARE THE PRIMARY LIMITATIONS IN B-CELL AFFINITY MATURATION, AND HOW MUCH AFFINITY MATURATION CAN WE DRIVE WITH VACCINATION? A Role for Antibody Feedback Kai-Michael Toellner, Daniel M.-Y. DO MEMORY CD4 T CELLS KEEP THEIR CELL-TYPE PROGRAMMING: PLASTICITY VERSUS FATE COMMITMENT? Epigenome: A Dynamic Vehicle for Transmitting and Recording Cytokine Signaling John L. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |